The Experts below are selected from a list of 93744 Experts worldwide ranked by ideXlab platform

Myeong Chan Cho - One of the best experts on this subject based on the ideXlab platform.

Kyung Hoon Cho - One of the best experts on this subject based on the ideXlab platform.

Deborah Wentworth - One of the best experts on this subject based on the ideXlab platform.

  • serum Cholesterol Level and mortality findings for men screened in the multiple risk factor intervention trial
    JAMA Internal Medicine, 1992
    Co-Authors: James D Neaton, Henry Blackburn, David R Jacobs, Lewis H Kuller, Duck Joo Lee, Roger Sherwin, Joanna Shih, Jeremiah Stamler, Deborah Wentworth
    Abstract:

    Background.— With increased efforts to lower serum Cholesterol Levels, it is important to quantify associations between serum Cholesterol Level and causes of death other than coronary heart disease, for which an etiologic relationship has been established. Methods.— For an average of 12 years, 350 977 men aged 35 to 57 years who had been screened for the Multiple Risk Factor Intervention Trial were followed up following a single standardized measurement of serum Cholesterol Level and other coronary heart disease risk factors; 21 499 deaths were identified. Results.— A strong, positive, graded relationship was evident between serum Cholesterol Level measured at initial screening and death from coronary heart disease. This relationship persisted over the 12-year follow-up period. No association was noted between serum Cholesterol Level and stroke. The absence of an association overall was due to different relationships of serum Cholesterol Level with intracranial hemorrhage and nonhemorrhagic stroke. For the latter, a positive, graded association with serum Cholesterol Level was evident. For intracranial hemorrhage, Cholesterol Levels less than 4.14 mmol/L ( Conclusions.— The association of serum Cholesterol with specific causes of death varies in direction, strength, gradation, and persistence. Further research on the determinants of low serum Cholesterol Level in populations and long-term follow-up of participants in clinical trials are necessary to assess whether inverse associations with noncardiovascular disease causes of death are consequences of noncardiovascular disease, whether serum Cholesterol Level and noncardiovascular disease are both consequences of other factors, or whether these associations are causal. ( Arch Intern Med . 1992;152:1490-1500)

  • serum Cholesterol Level and mortality findings for men screened in the multiple risk factor intervention trial multiple risk factor intervention trial research group
    JAMA Internal Medicine, 1992
    Co-Authors: James D Neaton, Henry Blackburn, David R Jacobs, Lewis H Kuller, Duck Joo Lee, Roger Sherwin, Joanna Shih, Jeremiah Stamler, Deborah Wentworth
    Abstract:

    Background With increased efforts to lower serum Cholesterol Levels, it is important to quantify associations between serum Cholesterol Level and causes of death other than coronary heart disease, for which an etiologic relationship has been established. Methods For an average of 12 years, 350,977 men aged 35 to 57 years who had been screened for the Multiple Risk Factor Intervention Trial were followed up following a single standardized measurement of serum Cholesterol Level and other coronary heart disease risk factors; 21,499 deaths were identified. Results A strong, positive, graded relationship was evident between serum Cholesterol Level measured at initial screening and death from coronary heart disease. This relationship persisted over the 12-year follow-up period. No association was noted between serum Cholesterol Level and stroke. The absence of an association overall was due to different relationships of serum Cholesterol Level with intracranial hemorrhage and nonhemorrhagic stroke. For the latter, a positive, graded association with serum Cholesterol Level was evident. For intracranial hemorrhage, Cholesterol Levels less than 4.14 mmol/L (less than 160 mg/dL) were associated with a twofold increase in risk. A serum Cholesterol Level less than 4.14 mmol/L (less than 160 mg/dL) was also associated with a significantly increased risk of death from cancer of the liver and pancreas; digestive diseases, particularly hepatic cirrhosis; suicide; and alcohol dependence syndrome. In addition, significant inverse graded associations were found between serum Cholesterol Level and cancers of the lung, lymphatic, and hematopoietic systems, and chronic obstructive pulmonary disease. No significant associations were found of serum Cholesterol Level with death from colon cancer, with accidental deaths, or with homicides. Overall, the inverse association between serum Cholesterol Level and most cancers weakened with increasing follow-up but did not disappear. The association between Cholesterol Level and death due to cancer of the lung and liver, chronic obstructive pulmonary disease, cirrhosis, and suicide weakened little over follow-up. Conclusions The association of serum Cholesterol with specific causes of death varies in direction, strength, gradation, and persistence. Further research on the determinants of low serum Cholesterol Level in populations and long-term follow-up of participants in clinical trials are necessary to assess whether inverse associations with noncardiovascular disease causes of death are consequences of noncardiovascular disease, whether serum Cholesterol Level and noncardiovascular disease are both consequences of other factors, or whether these associations are causal.

Philip A Wolf - One of the best experts on this subject based on the ideXlab platform.

  • Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease
    2017
    Co-Authors: Zaldy S. Tan, Sudha Seshadri, Alexa Beiser, Peter W F Wilson, Douglas P Kiel, Michael Tocco, Philip A Wolf
    Abstract:

    Background: Previous studies examining the association of plasma Cholesterol Levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total Cholesterol Levels averaged across many years on the risk for AD in a large, population-based cohort. Methods: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total Cholesterol Levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total Cholesterol Levels across biennial examination cycles 1 to 15 and baseline total Cholesterol Level measured at the 20th biennial examination cycle. Results:Alzheimerdiseasedevelopedin77subjectsfrom 1992 to 2000. After adjustment for age, sex,APOEgenotype, smoking, body mass index (calculated as weight in kilogramsdividedbythesquareofheightinmeters),coronary heart disease, and diabetes, we found no significantassociationbetweentheriskforincidentADandaverage Cholesterol Level at biennial examination cycles 1 to15(hazardratioper10-mg/dL[0.3-mmol/L]rise,0.95; 95%confidenceinterval,0.87-1.04)orbaselinetotalCholesterol Level at examination 20 (hazard ratio, 0.97; 95% confidence interval, 0.90-1.05). Conclusion:Inthislarge,population-basedcohort,baseline and long-term average serum total Cholesterol Levels were not associated with the risk for incident AD. Arch Intern Med. 2003;163:1053-1057

  • plasma total Cholesterol Level as a risk factor for alzheimer disease the framingham study
    JAMA Internal Medicine, 2003
    Co-Authors: Sudha Seshadri, Alexa Beiser, Peter W F Wilson, Douglas P Kiel, Michael Tocco, Ralph B Dagostino, Philip A Wolf
    Abstract:

    Background Previous studies examining the association of plasma Cholesterol Levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total Cholesterol Levels averaged across many years on the risk for AD in a large, population-based cohort. Methods Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total Cholesterol Levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total Cholesterol Levels across biennial examination cycles 1 to 15 and baseline total Cholesterol Level measured at the 20th biennial examination cycle. Results Alzheimer disease developed in 77 subjects from 1992 to 2000. After adjustment for age, sex,APOEgenotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average Cholesterol Level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95% confidence interval, 0.87-1.04) or baseline total Cholesterol Level at examination 20 (hazard ratio, 0.97; 95% confidence interval, 0.90-1.05). Conclusion In this large, population-based cohort, baseline and long-term average serum total Cholesterol Levels were not associated with the risk for incident AD.

Bangdang Chen - One of the best experts on this subject based on the ideXlab platform.